Treatment Outcomes Under a Standardized Treatment Protocol in Patients Suffered Substance Abuse Related Voiding Dysfunction
Study Details
Study Description
Brief Summary
With the increase of substance abuse over the world, substance abuse e.g. ketamine and methamphetamine related voiding dysfunction is becoming an important medical problem. However, while the clinical manifestation of the condition is becoming better defined, the underlying pathophysiology is still poorly understood. Moreover, majority of the current treatment is just based on the experience on some small case series and there is no treatment data for larger patient sample or standard recommended treatment in the literature. In order to improve the management of this condition, investigators have formulated a treatment protocol based on the current literatures on the management of voiding dysfunction and also a similar condition, interstitial cystitis / painful-bladder syndrome (IC/PBS). The protocol basically consists of the following modalities:
-
Basic information and education on the condition, principle of treatment and psychosocial support.
-
First line treatment will include a course of oral anti-inflammatory drugs (for the control of the inflammation process and pain) and anticholinergic agents (for the irritative urinary symptoms).
-
If these simple oral medication are found to be not effective, then further treatment will include other oral medications, such as amitriptyline and gabapentin, and some drugs that directly applied into the bladder cavity (hyaluronate) or bladder muscle (botulinum toxin).
-
For those patients with intractable symptoms and failed all the above treatments, surgical treatment (hydrodistension, augmentation cystoplasty) will be discussed.
The purpose of this research is to assess the effectiveness of the above treatment protocol in the management of substance induced voiding dysfunction and also assess any possible adverse events related to the usage of the drugs.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
With the increase in recreational usage of various soft drugs, such as ketamine, methamphetamine over the world, substance abuse related voiding dysfunction is becoming an important medical problem. However, while the clinical manifestation of the condition is becoming better defined, the underlying pathophysiology is still poorly understood. Moreover, majority of the current treatment is based on the experience on some small case series and there is no treatment data for larger patient sample or standard recommended treatment in the literature. With the rapid increase in patients' demand, there is an urgent need for better clinical study on the effect of various treatment regimes for the condition, to provide more evidence-based recommendation for them. On the other hand, better treatment outcome will also help the rehabilitation of these substance abusers.
However, in Hong Kong, due to the limited funding in the tertiary care health system and the poor social support for the patients, some potential treatment options, including COX II inhibitors, intravesical hyaluronate, and botulinum toxin injection, etc, are not readily available for these patients. Therefore, some patients may receive sub-optimal treatment with more side effects or may have limited access to certain therapeutic options. The patients may have to suffer and this also affects the doctors' experience and hence the formulation of ideal treatment for these patients. If extra or adequate funding is available, it may not only widen the potential treatment options for these patients but also provide more clinical experience and data in guiding the formulation of treatment protocols / recommendation and even guide future research direction.
Therefore, in this proposal, investigators would like to prospectively study the treatment result of various treatment modalities under a standardized treatment protocol. The results will help to evaluate the effectiveness and also tolerability of various proposed treatment options in substance abused related voiding dysfunction. . Because of the certain similarities in the clinical manifestations and pathology of voiding dysfunction and interstitial cystitis / painful-bladder syndrome (IC/PBS), this treatment protocols (referred to later section) will base on standard recommendations of IC/PBS (including the American Urological Guideline) and literature on voiding dysfunction management. For treatment / medications that are not provided in Hospital Authority formulation, investigators will provide to patient if clinically indicated. Currently, because of the insufficient treatment data and also the behavioural characteristics of these substance abusers, it will be difficult or impractical to perform randomized placebo-controlled clinical trials in this area. As a result, a prospective longitudinal study on a standardized treatment protocol is proposed, which will provide some "Real-life practice" information on the management of these patients. The data gathered from this study may also provide basis for future study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| substance abuse group Patients with voiding dysfunction secondary to substance abuse in a special clinic |
Drug: First line treatment: oral NSAID and anticholinergic agents
oral NSAID and anticholinergic agents
Drug: Second line treatment: additional treatment for pain control
Gabapentin, tramadol, Lyrica
Drug: Third line treatment: A course of intravesical hyaluronate will be given.
A course of intravesical hyaluronate will be given.
Procedure: Fourth line treatment: surgical intervention
Consideration of hydrodistention and augmentation cystoplasty
|
Outcome Measures
Primary Outcome Measures
- Change in total Bladder Capacity after standardized treatment. [Baseline, 4 months, 8 months, 12 months, every 4 months through study completion, and average of 1 year]
Total bladder capacity is assessed by the sum of voided volume and post-voided volume
- Change in Pain level after standardized treatment: Pelvic Pain - Urgency Frequency symptom scale [Baseline, 4 months, 8 months, 12 months, every 4 months through study completion, and average of 1 year]
Using the Pelvic Pain - Urgency Frequency symptom scale
- Change in Bladder storage function after standardized treatment [Baseline, 4 months, 8 months, 12 months, every 4 months through study completion, and average of 1 year]
Using Overactive Bladder Symptom Score
- Change in Bladder voiding function after standardized treatment [Baseline, 4 months, 8 months, 12 months, every 4 months through study completion, and average of 1 year]
Using the International Prostate Symptom Score
- Any new Adverse events related to treatment modalities [Baseline, 4 months, 8 months, 12 months, every 4 months through study completion, and average of 1 year]
By patient reporting
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients suffered substance abuse induced voiding dysfunction
Exclusion Criteria:
-
Patient not agreed for consent
-
Patient that will not comply to our treatment protocol
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Prince of Wales Hospital | Shatin | Hong Kong |
Sponsors and Collaborators
- Chinese University of Hong Kong
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Dimitrakov J, Kroenke K, Steers WD, Berde C, Zurakowski D, Freeman MR, Jackson JL. Pharmacologic management of painful bladder syndrome/interstitial cystitis: a systematic review. Arch Intern Med. 2007 Oct 8;167(18):1922-9. Review. Erratum in: Arch Intern Med. 2007 Dec 10-22;167(22):2452.
- Hanno P, Lin A, Nordling J, Nyberg L, van Ophoven A, Ueda T, Wein A; Bladder Pain Syndrome Committee of the International Consultation on Incontinence. Bladder Pain Syndrome Committee of the International Consultation on Incontinence. Neurourol Urodyn. 2010;29(1):191-8. doi: 10.1002/nau.20847. Review.
- Marinkovic SP, Moldwin R, Gillen LM, Stanton SL. The management of interstitial cystitis or painful bladder syndrome in women. BMJ. 2009 Jul 31;339:b2707. doi: 10.1136/bmj.b2707. Review.
- Middela S, Pearce I. Ketamine-induced vesicopathy: a literature review. Int J Clin Pract. 2011 Jan;65(1):27-30. doi: 10.1111/j.1742-1241.2010.02502.x. Review.
- Smith HS. Ketamine-induced urologic insult (KIUI). Pain Physician. 2010 Nov-Dec;13(6):E343-6.
- Wood D, Cottrell A, Baker SC, Southgate J, Harris M, Fulford S, Woodhouse C, Gillatt D. Recreational ketamine: from pleasure to pain. BJU Int. 2011 Jun;107(12):1881-4. doi: 10.1111/j.1464-410X.2010.10031.x. Epub 2011 Feb 14. Review.
- CRE-2011.454